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Abstract  
 
Background: Medulloblastoma and primitive neuroectodermal tumours (PNET) are the 
most common central nervous system (CNS) embryonal tumours diagnosed in childhood. 
Survival outcomes are worse for children diagnosed with CNS PNET compared to 
medulloblastoma. Less is known about survival outcomes in teenagers and young adults 
(TYA).   
Methods: Data were extracted from two population-based cancer registries of children and 
young people (0-24 years) in the north of England for all diagnoses of medulloblastoma and 
CNS PNET between 1990 and 2013. Incidence and survival trends were analysed using 
Poisson and Cox regression.  
Results: Between 1990 and 2013, 197 medulloblastomas and 58 CNS PNET were 
diagnosed; age standardised incidence rates of 3.8 and 1.5 per million, respectively. 
Medulloblastoma incidence decreased over time while there was no significant change in 
trend for CNS PNET. The overall 5 year survival rate was 54%. The risk of death was 2.4 
times higher (95%CI 1.6, 3.7) for patients with CNS PNET compared to medulloblastoma, 
after adjustment for patient characteristics. There was a 39% reduction (95%CI 0.43, 0.87) in 
the risk of death for patients diagnosed between 2000 and 2013 compared to 1990-1999. 
Risk of death did not differ for TYA (15-24 years) compared to children aged 5-9 years.  
Conclusions:  Medulloblastoma incidence decreased over time and differences in survival 
between medulloblastoma and PNET emerged within the first year post diagnosis leading to 
poorer outcomes for children and young adults diagnosed with PNET, however a significant 
improvement in survival over time was observed.  
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Highlights  
 Little is known about incidence  and survival outcomes in teenagers and young adults 
(TYA) with CNS embryonal tumours 
 Incidence trends decreased over time for medulloblastoma, however no significant 
trend was observed for CNS PNET over time  
 Differences in survival between medulloblastoma and CNS PNET emerged within the 
first year post diagnosis 
 There was an improvement in survival over time for children and TYA with 
medulloblastoma and CNS PNET 
 There were no differences in survival between TYA compared to children aged 5-9 
years 
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Introduction 
Central nervous system (CNS) tumours are the second most common site of neoplasms 
diagnosed in children, accounting for approximately one quarter of all childhood cancers (0-
14 years), (1) and 14% of tumours diagnosed in teenagers and young adults (TYA) (15-24 
years) (2). They are the most common cause of cancer related death in children and TYA (1, 
2).  
 
CNS embryonal tumours are the second most frequent CNS subgroup of tumours in 
childhood, (3) which are further classified into one of four groups based on morphology and 
topography according to the International Classification of Cancer in Children version 3 
(ICCC-3) (4): medulloblastoma, primitive neuroectodermal tumours (CNS PNET), 
medulloepitheliomas and atypical teratoid/rhabdoid tumours (ATRT). Medulloblastomas are 
the most common embryonal tumours (3, 5). CNS PNETs are rare; in England between 
1995 and 2003 there were an estimated average of 15 new cases per year in children and 5 
per year in TYA, compared with 44 and 7 cases of medulloblastoma in children and TYA 
respectively (6).   
 
In recent years, molecular testing of CNS tumours has evolved. Medulloblastomas are 
considered to comprise at least four distinct diseases that differ according to their 
demographic characteristics, histology, genetics and clinical outcomes (7-9). The CNS 
PNET subgroup refers to a heterogeneous group of tumours that show aggressive clinical 
behaviour. Specific histotypes with distinct molecular features have recently been identified 
such as embryonal tumour with abundant neuropil and true rosettes (ETANTR) (10, 11).  
Moreover, a significant proportion have molecular phenotypes more characteristic of other 
tumour types such as ependymomas and high grade gliomas, suggesting that histological 
appearance alone may be inadequate to accurately classify many of these tumours (12-14). 
However these distinctions are not yet clarified in either the 2007 World Health Organisation 
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classification of CNS tumours or the ICCC-3 and historical cancer registration data comprise 
very little, if any, information on molecular status.   
 
Population- based studies which have analysed survival rates separately for 
medulloblastoma and CNS PNET have shown that children diagnosed with medulloblastoma 
have better survival outcomes than those with CNS PNET (5-year survival rates range 
between 58-69% for medulloblastoma vs. 27-47% for CNS PNET) (3, 15-18).  The incidence 
of childhood CNS embryonal tumours increased in Europe between 1978 and 1997 (19). 
Analysis by subgroup in children in Germany found that incidence trends for 
medulloblastoma in children have remained stable between 1991 and 2012 while over the 
same period the PNET rate decreased mainly due to improved diagnostic tools and 
classification of tumours (18).   
 
Previous studies of incidence and survival of CNS embryonal tumours have generally been 
limited to children only. The aim of this study was to describe patterns and trends in 
incidence and survival of children and young people, aged 0-24 years, diagnosed with CNS 
embryonal tumours in the North of England focusing specifically on medulloblastomas and 
CNS PNET adjusting survival for patient case-mix including treatment.    
 
Patients and methods 
This study used data from two geographically adjacent population based tumour registers in 
the north of England; the Yorkshire Specialist Register of Cancer in Children and Young 
People (YSRCCYP) and the Northern Region Young Person’s Malignant Disease Register 
(NRYPMDR) (Figure 1). YSRCCYP collects information on children and young people aged 
0-29 years at diagnosis whilst resident in the Yorkshire area (0-29 year population of 2 
million in 2011) (20). Case ascertainment was complete for all patients aged under 30 years 
resident in the former Yorkshire Health authority from 1990 onwards; patients resident in the 
South Yorkshire Strategic Health Authority part of the region were included in the register 
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between 1998 and 2013 for children (0-14 years) and between 1998 and 2009 for teenagers 
and young adults (15-29 years). The NRYPMDR covers the counties of Northumberland, 
Tyne and Wear, Durham, Teesside and Cumbria (excluding Barrow-in-Furness) (0-24 year 
population of 0.9 million in 2011) and has recorded information on all cases of cancers in the 
region diagnosed in 0-24 year olds since 1968 (21). For both registers cases are identified 
through multiple sources including: hospital records, neuropathology reports, hospital 
admissions, other regional and national cancer registries (20, 21). Patients are regularly 
followed up to determine current status.  
 
All tumours were classified into a histological group according to ICCC-3 (4). The group of 
embryonal tumours (ICCC-3 IIIc) can be further broken down into one of four subgroups; 
medulloblastoma, CNS PNET, medulloepitheliomas and Atypical teratoid/rhabdoid tumours 
(ATRT) (4). Medulloepitheliomas have recently been identified to be the same pathological 
entity as ETANTRs, many of which would have been previously classified as CNS PNETs.  
Therefore for this analysis medulloepitheliomas have been included in the CNS PNET group. 
ATRT are excluded from further analysis due to small numbers.  
 
All diagnoses of CNS tumours between 1990 and 2013 in patients aged 0-24 years were 
extracted from the YSRCCYP and the NRYPMDR. Only first, primary tumours within each 
patient were analysed. We extracted information on each patient’s age at diagnosis, gender, 
treatment received, date of diagnosis and date of death or last follow-up. All cases were 
followed up until death or a censor date of 31/12/2014. Deprivation was measured using the 
area-based Townsend index derived from the 2001 UK census based (22).    
 
Information on the treatment modality each individual received was classified into one of six 
groups: surgery, radiotherapy and chemotherapy; surgery alone; surgery and radiotherapy; 
surgery and chemotherapy; adjuvant therapy without surgery (including radiotherapy and 
chemotherapy, radiotherapy alone or chemotherapy alone); and no treatment recorded. The 
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treatment patterns for medulloblastoma changed over the study period with the introduction 
of reduced dose radiation therapy and adjuvant chemotherapy in 1999 (23). We defined the 
period of diagnosis as either 1990-1999 or 2000-2013 to reflect changes in treatment over 
the study period.   
 
Statistical analysis 
Direct age standardised incidence rates (ASR) adjusted to the World standard population 
were calculated and reported per 1,000,000 person-years by gender and period of diagnosis 
(24). For incidence rate trends the age and sex adjusted average annual percent change 
(AAPC) was estimated by Poisson regression. Kaplan Meier 1, 2, 5 and 10 year survival 
estimates were calculated separately for medulloblastoma and CNS PNET. Cox proportional 
hazards models were used to model survival trends. Multivariable models included variables 
for diagnostic subgroup, age at diagnosis, gender, period of diagnosis, area deprivation and 
treatment. Tumour grade at diagnosis was not included in the model as all cases were 
classified as WHO grade IV (12). Additionally interaction terms between (a) diagnostic 
subgroup and period of diagnosis, (b) diagnostic subgroup and gender, and (c) diagnostic 
subgroup and age at diagnosis were included in the models to formally test if there were 
differences in survival patterns by diagnostic subgroup over time, by gender or by age 
groups. The proportional hazards assumption was checked for each variable using the 
Therneau and Grambsch test (25) within Stata (26). This assumption was met for all 
variables except treatment; we stratified the model across treatment categories and found 
the proportional hazards assumption to hold for all other variables.  
 
Conditional 5 year survival was calculated separately for each diagnostic subgroup. 
Conditional survival is the probability of surviving an additional x years given that the person 
has already survived y years and is calculated by dividing the (x+y) year cumulative survival 
by the y year cumulative survival (27). For example, the 5 year conditional survival of 
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patients who had survived 1 year was estimated by dividing the 6 year cumulative survival 
by the 1 year cumulative survival. This measure shows how the survival probability changes 
with increasing duration of follow-up from the time of initial cancer diagnosis (27).      
 
Incidence and survival rates by subgroup were compared with those published in the 
literature from population based cancer registries within the age range 0-24 years and 
covering time periods that overlapped with this study.  
 
Results 
Incidence  
Between 1990 and 2013 there were 277 children and young people diagnosed with a CNS 
embryonal tumour; medulloblastomas were the most common type (n=197, 71%), followed 
by CNS PNET (n=58, 21%), and a further 22 (8%) patients were diagnosed with ATRT (this 
group was excluded from further analysis) (Table 1).   
 
The overall ASRs for medulloblastoma and CNS PNET were 3.8 and 1.5 per 1,000,000 
person-years respectively. Between 1990 and 2013 there was a statistically significant 
decreasing trend for medulloblastoma (AAPC= -2.3% (95%CI -4.4, -0.3)) and no significant 
change for CNS PNET (AAPC= -1.8% (95%CI -5.6, 2.0)) (figure 2).  
 
Survival  
Survival rates were considerably lower for CNS PNET compared to medulloblastoma; 5 year 
survival rates were 33% (95%CI (21, 46)) and 64% (95% CI (56, 70)), respectively (table 2). 
Unadjusted survival rates were better for cases diagnosed between 2000 and 2009 
compared to those diagnosed between 1990 and 1999 for medulloblastoma only (table 2). 
For medulloblastoma there were no survival differences between children and TYA, however 
for CNS PNET TYA had slightly higher survival rates (Table 2). 
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The adjusted risk of death was 2.4 times higher for CNS PNET compared to 
medulloblastoma (HR=2.4, 95%CI (1.6, 3.7) table 3). Age was also significantly associated 
with survival with an increased risk of death in those aged 0-4 years compared to those aged 
5-9 years at diagnosis, but there was no difference in survival for TYAs compared to 5-9 
year olds. Survival improved over time, with a significant 37% reduction in the risk of death 
for patients diagnosed between 2000 and 2013 compared to 1990-1999 (HR=0.63, 95%CI 
(0.43, 0.92)). The risk of death increased by 30% for patients with a deprivation score on the 
75th percentile compared to those on the 25th percentile (HR=1.3, 95%CI (1.0, 1.6)). There 
were no significant interactions between diagnostic subgroup and period of diagnosis 
(p=0.21), diagnostic subgroup and gender (p=0.84) or diagnostic subgroup and age 
(p=0.46).   
 
For both diagnostic subgroups conditional survival increased for every additional year 
survived. Although the initial prognosis was worse for CNS PNET compared to 
medulloblastoma, for those who survived 3 years from diagnosis, the conditional 5-year 
survival rates were similar in both groups (85% for medulloblastoma and CNS PNET) 
(Figure 3).  
 
International comparisons 
Table 4 compares incidence and survival rates by diagnostic subgroup from our study with 
published population based studies including 5 in Europe and 1 from the USA. 
Medulloblastoma survival in 0-14 year olds in the North of England was slightly lower than in 
Germany over a very similar time period (63% and 69% respectively) but higher than that in 
Great Britain between 1991 and 2000 (58%). Our childhood CNS PNET survival rates were 
lower than those in Germany, France and Sweden but our CNS PNET group also included 
medulloepithelioma, recognised to have a particularly aggressive clinical course, which other 
studies included as a separate group.   
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Discussion  
CNS tumours are the most common cause of cancer related death in children and TYA; 15% 
of children and 9% of TYA diagnosed with CNS tumours die within one year of diagnosis 
(28, 29), however little is known about how this varies by diagnostic subgroup. CNS 
embryonal tumours generally have poor prognosis and this study adds to the existing 
literature by describing trends in medulloblastoma and CNS PNET incidence and survival 
and includes teenagers and young adults aged 15- 24 years for whom comparatively little is 
known about disease epidemiology.  
 
Over time the incidence trend for CNS embryonal tumours remained stable but there were 
differences by subtype with a significant decreasing incidence trend for medulloblastoma. 
We found that the 5 year overall survival rate for CNS embryonal tumours diagnosed aged 
0-24 years was 54%. However, this masked clear differences according to diagnostic 
subtype with significantly poorer five-year survival rates seen for CNS PNET (33%) 
compared to medulloblastoma (64%) with differences emerging within the first year after 
diagnosis. The relative risk of death was 2.4 times higher for patients with CNS PNET 
compared to medulloblastoma, after adjustment for patient case-mix. Encouragingly, survival 
rates improved over time, driven by an increase for medulloblastoma. The risk of death was 
greatest in those aged 0-4 years, and there were no differences in survival between older 
children and TYA or by gender. Our conditional survival results showed that although CNS 
PNET prognosis was poor (one year survival rate 64%), for the small group of patients who 
survive three years from diagnosis the survival probabilities for the next 5 years were similar 
for medulloblastoma and CNS PNET.  
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CNS PNET are a heterogeneous group of tumours that can be difficult to classify and 
historically many CNS PNETs may have been misdiagnosed high grade gliomas with poor 
survival outcomes (13, 14). Improvements in molecular testing of CNS PNET will result in 
less misclassification of these tumours and is likely that this will impact of future incidence 
and survival estimates; indeed the observed decreasing trend in medulloblastoma incidence 
in this study may be due to improvements in classification over time.   
 
Across Europe survival rates improved for children diagnosed with CNS tumours and in 
particular CNS embryonal tumours between 1995 and 2002 (30). Other studies have also 
shown a general improvement in survival for childhood CNS tumours over the last 20-30 
years identifying improvements in CNS embryonal tumour survival specifically (3, 16, 19, 30, 
31). TYA, aged 16-24 years, from Yorkshire showed a significant increase in survival from 
medulloblastoma and CNS PNET combined  between 1990 and 2009 (32). As one of the 
few studies to consider children and TYA together over an extended time period and 
uniquely able to account for the effects of treatment modality, we observed an improvement 
in survival rates over time, with better survival in patients diagnosed after 2000 compared to 
those diagnosed in the 1990s. This statistically significant difference was only evident after 
adjustment for treatment. This finding reflects the timing of the changes in treatment patterns 
with the introduction of reduced dose radiation therapy and adjuvant chemotherapy (23).  
 
We compared our survival rates to those from other international studies and found 
childhood medulloblastoma rates are similar to those in France (16) and Sweden (15) but 
are slightly lower than those in Germany (18). It is difficult to directly compare our CNS 
PNET rates as we included medulloepithelioma in our grouping which have particularly poor 
outcomes. International comparisons of CNS PNET are difficult due to differences in 
diagnostic procedures. No studies looked specifically at these subgroups in 15-24 years 
olds. Data from the US between 2001 and 2006 have shown that survival rates for 
medulloblastoma and CNS PNET were similar in children aged 1-9 years and adolescents 
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aged 10-19 years (17). In our study we did not find a difference in survival between the TYA 
age group and children aged 5-9 years. We did however observe a doubling of the risk of 
death for those aged under 5 years, consistent with other studies (3, 5, 15-19, 31) due to 
treatment strategies for infants and young children that defer or avoid radiation (7).    
 
Notable strengths of our study include detailed data on patient characteristics particularly 
treatment received allowing us to adjust for patient case-mix. The main limitation of this 
study is the lack of information on molecular status of the tumours. Although distinct 
subgroups of medulloblastoma and CNS PNET have been established (7-13), these 
subgroups are not as yet classified as separate entities according to WHO or the ICCC-3. 
The recent progress in classification should lead to new biomarkers that can be used in 
clinical practice to improve risk stratification and adapt existing and new treatments to each 
patient (33, 34).  
 
In conclusion, we found a decreasing incidence trend for medulloblastoma and differences in 
survival between medulloblastoma and CNS PNET which appeared within the first year post 
diagnosis leading to poorer outcomes for children and young adults diagnosed with CNS 
PNET. The risk of death was lower for patients diagnosed after 2000, and was highest in 
infants and young children, although there were no survival differences for TYA compared to 
children aged 5-9 years or by gender. 
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Table and figure title and footnotes 
Table 1: Patient characteristics and age standardised incidence rates (ASR)  
  Medulloblastoma   CNS PNET   All CNS embryonal tumours* 
Characteristic n (%) ASR (95%CI)   n (%) ASR (95%CI)   n (%) ASR (95%CI) 
Total 197 3.8 (3.3, 4.3)   58 1.5 (1.2, 1.9)   277 5.3 (4.7, 6.0) 
Gender 
        
Male 119 (60%) 4.5 (3.7, 5.3) 
 
36 (62%) 1.9 (1.4, 2.4) 
 
169 (61%) 6.4 (5.4, 7.4) 
Female 78 (40%) 3.1 (2.4, 3.8) 
 
22 (38%) 1.2 (0.8, 1.6) 
 
108 (39%) 4.3 (3.5, 5.1) 
Male:Female ratio 1.5 
  
1.6 
  
1.6 
 
Age group 
        
0-4 years 65 (33%) - 
 
20 (35%) - 
 
99 (36%) - 
5-9 years 79(40%) - 
 
15 (26%) - 
 
98 (35%) - 
10-14 years 36 (18%) - 
 
8 (14%) - 
 
47 (17%) - 
15-19 years 12 (6%) - 
 
8 (14%) - 
 
21 (8%) - 
20-24 years 5 (3%) - 
 
7 (12%) - 
 
12 (4%) - 
Period of diagnosis 
        
1990-1999 88 (45%) 4.3 (3.4, 5.2) 
 
28 (48%) 1.4 (0.9, 1.9) 
 
117 (42%) 5.6 (4.6, 6.7) 
2000-2013 109 (55%) 3.5 (2.8, 4.1) 
 
30 (52%) 1.7 (1.2, 2.1) 
 
160 (58%) 5.1 (4.3, 6.0) 
Treatment  
        
Surgery, radiotherapy and chemotherapy 104 (53%) 
  
20 (34%) 
  
130 (47%) 
 
Surgery alone 19 (10%) 
  
12 (21%) 
  
35 (13%) 
 
Surgery and radiotherapy 19 (10%) 
  
5 (9%) 
  
24 (9%) 
 
Surgery and chemotherapy 36 (18%) 
  
12 (21%) 
  
58 (21%) 
 
Other treatment 11 (6%) 
  
6 (10%) 
  
18 (7%) 
 
No treatment recorded  8 (4%)     3 (5%)     12 (4%)   
Footnote: ASR = Directly age standardised incidence rate, adjusted to World standard population, per 1,000,000 population 
* All CNS Embryonal includes medulloblastoma (n=197), CNS PNET (n=58) and Atypical tertoid/rhabdoid tumours (n=22)
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Table 2: One, two, five and ten year Kaplan-Meier overall survival estimates by diagnostic 
sub group, period of diagnosis and age group.  
 % survival  (95% CI) 
Diagnostic subgroup 1 year 2 year 5 year 10 year 
All Embryonal  
    
All years 76 (71, 81) 63 (57, 68) 54 (48, 60) 45 (39, 52) 
1990-1999 73 (64, 80) 59 (50, 67) 50 (40, 58) 41 (32, 50) 
2000-2013 79 (72, 85) 66 (58, 72) 58 (49, 65) 49 (40, 57) 
Age group 
    
0-14 years 74 (68, 79) 62 (55, 68) 54 (47, 60) 46 (39, 52) 
15-24 years 91 (74, 97) 69 (50, 82) 59 (40, 74) 42 (22, 61) 
Medulloblastoma  
    
All years  83 (77, 87) 72 (65, 78) 64 (56, 70) 55 (47, 62) 
1990-1999 77 (67, 85) 64 (53, 73) 55 (44, 64) 47 (63, 57) 
2000-2013 87 (79, 92) 78 (69, 85) 71 (61, 79) 61 (50, 70) 
Age group 
    
0-14 years 82 (76, 87) 71 (64, 77) 63 (55, 70) 54 (46, 61) 
15-24 years 88 (61, 97) 76 (49, 90) 70 (41, 86) 56 (23, 79) 
CNS PNET  
    
All years 64 (50, 75) 46 (33,  58) 33 (21, 46) 23 (12, 35) 
1990-1999 57 (37, 73) 46 (28, 63) 36 (19, 53) 25 (11, 42) 
2000-2013 70 (50, 83) 46 (27, 62) 30 (15, 48) 15 (2, 43) 
Age group 
    
0-14 years 53 (38, 67) 39 (25, 53) 27 (15, 41) 19 (8, 34) 
15-24 years 93 (61, 99) 66 (36, 84) 51 (24, 73) 34 (11, 59) 
Footnote: PNET = Primitive neuroectodermal tumour 
 
  
17 
 
Table 3: Multivariable Cox regression model results  
Characteristic Adjusted HR† 95%CI 
Diagnostic subgroup     
Medulloblastoma 1 - 
CNS PNET 2.4 (1.6, 3.7) 
Gender 
  
Male 1 - 
Female 1.1 (0.8, 1.6)  
Age group 
  
0-4 years 2.1 (1.3, 3.3) 
5-9 years 1 - 
10-14 years 1.3 (0.8, 2.2) 
15-19 years 0.7 (0.3, 1.7) 
20-24 years 1.3 (0.6, 3.2) 
Period of diagnosis 
  
1990-1999 1 - 
2000-2013 0.63 (0.43, 0.92) 
Townsend deprivation 1.05 (1.0, 1.1) 
Footnote: HR = hazard ratio and 95% confidence interval (CI) 
† Model adjusted for all variables in table and treatment 
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Table 4: Comparison of incidence and survival estimates with published literature 
     Incidence Survival 
Study Region Diagnosis 
period 
Age range Diagnostic 
subgroup 
ASR  1 year (%) 5 year (%) 
This publication North of England 1990-2013 0-24 years Medulloblastoma 3.8 83 64 
CNS PNET† 1.5 64 33 
0-14 years Medulloblastoma 5.5 82 63 
CNS PNET† 2.0 53 27 
15-24 years Medulloblastoma 0.7 88 70 
CNS PNET† 0.7 93 51 
Tulla et al, 2015 (18) Germany 1991-2012 0-14 years Medulloblastoma  5.4 - 69 
CNS PNET 1.3 - 38 
Desandes et al, 2014 
(16) 
France  2000-2008 0-14 years Medulloblastoma  5.4 87 65 
CNS PNET  1.1 58 34 
Smoll, 2012 (17) US (SEER) 2001-2006 <1 year Medulloblastoma - 52 42 
1-9 years Medulloblastoma - 90 72 
10-19 years Medulloblastoma - 92 69 
<1 year CNS PNET - 31 14 
1-9 years CNS PNET - 88 64 
10-19 years CNS PNET - 94 57 
Lannering et al, 2009 
(15) 
Sweden 1984-2005 0-14 years Medulloblastoma  6.4 - 63 
CNS PNET 1.6 - 47 
Arora et al, 2008 (6) England 1995-2003 0-14 years Medulloblastoma  4.9 - - 
CNS PNET 1.7 - - 
   15-24 years Medulloblastoma  1.1 - - 
CNS PNET 0.8 - - 
Stiller, 2007 (3) Great Britain 1991-2000 0-14 years Medulloblastoma  4.8 81 58 
CNS PNET 1.6 56 27 
ASR = Directly age standardised incidence rate, adjusted to World standard population, per 1,000,000 population 
† In our study CNS PNET includes medulloepithelioma 
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Figure 1: Map of the combined geographic region covered by the Yorkshire Specialist 
Register of Cancer in Children and Young People and the Northern Region Young Person’s 
Malignant Disease Register 
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Figure 2: Trends in directly age-standardised (world population, per 1,000,000 person-
years) incidence rates for Medulloblastoma and CNS PNET in the north of England aged 0-
24 years, 1990-2013 
 
Footnote: PNET = Primitive neuroectodermal tumour 
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Figure 3: Conditional 5- year survival at 1, 2 and 3 years after diagnosis, by diagnostic 
subgroup, CNS embryonal tumours diagnosed in the north of England aged 0-24 years, 
1990-2013 
 
 
Footnote: PNET = Primitive neuroectodermal tumour 
 
